A study indicates that semaglutide may slow the progression of osteoarthritis and support cartilage repair in preclinical models as well as in small clinical samples. Researchers observed reductions in pathological joint changes, including cartilage degradation and osteophyte formation, along with decreased pain sensitivity. The mechanism did not appear to be driven solely by weight loss, previously thought to explain much of the drug’s benefit – semaglutide seems to act directly on the metabolism of cartilage cells.
The authors reported that semaglutide alters chondrocyte metabolism, shifting it from predominantly glycolysis toward oxidative phosphorylation, a change associated with enhanced tissue repair and regeneration.
Osteoarthritis is the most common form of arthritis worldwide, affecting hundreds of millions of people and causing pain, swelling, and reduced mobility. Current treatment strategies focus primarily on symptom management and functional improvement – there is no approved therapy that reverses the disease process itself or restores damaged cartilage.
Earlier research had already indicated that semaglutide may alleviate joint symptoms in individuals with obesity, likely due to weight reduction and the associated decrease in joint load. Clinical trials involving obese patients showed improved knee function and reduced pain, though these effects were largely attributed to weight loss.
The latest findings go further, highlighting a potential direct effect of semaglutide on joint cells independent of its slimming impact. However, experts caution that while the data are promising, they remain preliminary and require further clinical validation – particularly larger, controlled trials involving patients without obesity or with varying stages of disease to confirm these observations.